GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy

Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy

(2022) Thomas S. Uldrick et al.   Science Translational Medicine

Immune checkpoint blockade in HIV

(2022) Celine Gubser et al.   EBioMedicine

HIV-specific T-cell responses reflect substantive in vivo interactions with antigen despite long-term therapy

(2021) Eva M. Stevenson et al.   JCI Insight

Gag p24 is a Marker of HIV Expression in Tissues and Correlates with Immune Response

(2021) Guoxin Wu et al.   JOURNAL OF INFECTIOUS DISEASES

Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy

(2021) Chris Y. Chiu et al.   JOURNAL OF IMMUNOLOGY

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

(2021) Steven G. Deeks et al.   NATURE MEDICINE

Combination Immune Checkpoint Blockade to Reverse HIV Latency

(2020) Renée M. Van der Sluis et al.   JOURNAL OF IMMUNOLOGY

Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis

(2020) Leitao Sun et al.   Scientific Reports

First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors

(2020) Ravit Geva et al.   CANCER

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

(2020) Ani S. Balmanoukian et al.   CLINICAL CANCER RESEARCH

Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors

(2020) Kyriakos P. Papadopoulos et al.   CLINICAL CANCER RESEARCH

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals

(2019) Rémi Fromentin et al.   Nature Communications

Rational design of anti-GITR-based combination immunotherapy

(2019) Roberta Zappasodi et al.   NATURE MEDICINE

T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy

(2019) Bernard J.C. Macatangay et al.   AIDS

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

(2018) Ben Tran et al.   Journal for ImmunoTherapy of Cancer

Expansion of CD25-Negative Forkhead Box P3-Positive T Cells during HIV and Mycobacterium tuberculosis Infection

(2017) Matías T. Angerami et al.   Frontiers in Immunology

Rationale for anti-GITR cancer immunotherapy

(2016) Deborah A. Knee et al.   EUROPEAN JOURNAL OF CANCER

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

(2016) Glen M. Chew et al.   PLoS Pathogens

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART

(2016) Rémi Fromentin et al.   PLoS Pathogens

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

(2016) Mira A. Patel et al.   Journal for ImmunoTherapy of Cancer

Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+Regulatory T Cells Are Depleted

(2015) Young H. Kim et al.   JOURNAL OF IMMUNOLOGY

Enhanced CD8 T Cell Responses through GITR-Mediated Costimulation Resolve Chronic Viral Infection

(2015) Maria Fernanda Pascutti et al.   PLoS Pathogens

Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease

(2014) Leslie R. Cockerham et al.   AIDS

Anti-GITR Agonist Therapy Intrinsically Enhances CD8 T Cell Responses to Chronic Lymphocytic Choriomeningitis Virus (LCMV), Thereby Circumventing LCMV-Induced Downregulation of Costimulatory GITR Ligand on APC

(2014) Derek L. Clouthier et al.   JOURNAL OF IMMUNOLOGY

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

(2014) Lei Lu et al.   Journal of Translational Medicine

Modulation of Treg cells/T effector function by GITR signaling is context-dependent

(2013) Amal Ephrem et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Modulation of GITR for cancer immunotherapy

(2012) David A Schaer et al.   CURRENT OPINION IN IMMUNOLOGY

Maintaining the balance: Costimulatory TNFRs and control of HIV

(2012) Chao Wang et al.   CYTOKINE & GROWTH FACTOR REVIEWS

The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses

(2011) Brenda De Keersmaecker et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CD8 T Cell-Intrinsic GITR Is Required for T Cell Clonal Expansion and Mouse Survival following Severe Influenza Infection

(2010) L. M. Snell et al.   JOURNAL OF IMMUNOLOGY

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation

(2010) Adam D. Cohen et al.   PLoS One

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells

(2008) Johanna Kober et al.   EUROPEAN JOURNAL OF IMMUNOLOGY